Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Many of us took profits including the CEO back then. Times were good and the exuberance was at it's prime. $AVXL even filled the coffers with $150 million in cash. To say "Investor" made an outstanding call is nothing special as selling stock was the thing to do at that time. That was then, this is now.
AAIC was a bore, time for $AVXL to shine.
On the positive side, the mods do enforce "on topic" well.
True, but what's funny is I very frequently will click back on a response and read the ignored poster anyway.. LOL!
I like to read as many valid opinions as possible.
I'm a simpleton when it comes to biology, but I'm definitely not one when it comes to wealth management, so I value the quality contributions in topics I lack in.
iHub relies on ad revenue traffic and felt the need to keep up with stocktwits, hence the allowance of personal attacks. The era of non-personal attack trolling is over. It's a race to the bottom.
Or those who would have been his counterparty at capital firms were laid of in the investment bank downsizing of late.
I've been concerned about equity capital markets and the availability of capital for a couple years now and looking at the news and industry rags, biotech is in for some lean times.
Good thing $AVXL and a few others raised cash when the market was frothy.
New and unimproved iHub, now includes the fun of personal attacks...
I was a moderator/admin on this group and a "green rush" penny stock ($TRTC/$UNRV), which I trolled into the ground and saved many people from investing in its lies masqueraded in "forward looking statements" and rosy projections after the pump period was over and financial realities set into the sector.
This board has a few god posters, but doubtful it's still worth sifting through the multiple worthless trolling posts. The signal to noise ratio is getting smaller and that's unfortunate for new investors.
Definitely a most entertaining board.
LOL, just because you don't have the skill set for such earnings, don't take it out on another's success. Wealth envy is a weak bitch, as he earned it fair and square.
I wish someone had given me 500K FREE options subject to some condition
Combine that with Stanford president resignation and it's not a good look for the industry and/or academia.
Often times taxes are paid at the top rate and the cost basis is the same as the transaction often times market price.
But, I'm not a tax guy and situations can be different and laws change.
In your zealousness to spin the negative, try not to lie going forward.
In your zealousness to spin the negative, try not to lie going forward.
Indeed it was a neutral event and my viewpoint is similar to what I would recommend if Dr. M was my personal client, and that would have been at this juncture, a cashless exercise. Dr.M has a long tenure planned and lots of stock options available to reward him as per his employment contract.
$AVXL is a hobby stock of mine, a million dollar hobby, but it's a hobby. This message board is frequently toxic and it appears from the posts I've skimmed the rules have changed to be more toxic.
Between iHub, Stocktwits, and the FB group, each one has it's pros and cons.
Seek out the Facebook group if you want to further engage in positive dialogues. I'm one of the original creators and admin of the group. (It's a real person group, with real people not aliases). Fun factoid, It's where SOTC (Spirit of the Coast Analytics), the public facing entity of Mr. Mayomobile the smartest "kid" I've met in a long time, got it's start.
Actually the Doc's opinion agrees with mine in that the transaction was a neutral event as part of the CEO's compensation, and makes sense for clients who have many stock option grants as a part of their compensation.
I don’t read anything much good or bad into his decision. It’s a common choice for CEOs to make. It was the most neutral decision and regardless of outcomes with Rett, Missling will be just fine. However, it certainly doesn’t look like the CEO feels an AD AA NDA is forthcoming in months.
"To say "it was a gift" was a lie and here you go with more attempts to minimize and spin every event toward the negative.
To say "it was a gift" is a lie and wrong. It wasn't a gift. He received shares as part of his complementation plan.
Also, the cashless exercises made sense and IMO was the best option for Dr.M on a personal level. This is particularly true in his situation as stock option are a large part of his compensation and has many more option grants banked, and more to come as milestones are met.
At least I don't post the same drivel daily. The daily canned sniping and crying has the same effect as FUD.
Plenty of canned assumptions of next type of trial will be next too.
Hey Cornflakes, I have been "sucking it up" since 2015.
canned complaining on your part make one look like a blowhard...
Also what keeps getting missed in this discussion is that the value of the option grant is the CEO's FAIR and DUE compensation per his employment agreement written many, many years ago when $AVXL was a true OTC penny stock.
Bravo to Dr. M he earned it and good for him that he exercised in his own extremely rational way (cashless exercise) to add to his personal holdings.
Most long timers here before 2021 should be at worst, break even. Those like myself holding large profits also sold covered calls during the "irrational times". I can wait for the longer term value of blarcamesine to play out according to the CEO's instincts to unlock long term value.
Suck it up, biotech isn't for everyone. Don't blame poor investment selection and expectations on the CEO. First mistake is to assume there has been a "lack of progress".
Question for the patient longs: At what point do you get fed up with the glacial progress? What if we don't get the alz data in the 3rd quarter? What if there is no Rett NDA filed this year. What if there is no PD trial started this year? At what point does the lack of progress on milestones indicate deeper probelms?
It's been a long 8 years for me, but I too have learned more than when I arrived.
Plus, $AVXL is a much more fun story to tell.
Scrappy $AVXL the reverse merger, reverse split, OTC trading upstart who uplisted to NASDAQ versus "big money"
Sab, ACAD followed the traditional approach to financing (huge dilution, enrichment of insiders, VCs, etc.) whereas AVXL has not. ACAD is 98% owned by institutions and AVXL is ~35% owned by institutions. ACAD is relatively flat since 2014, whereas I think AVXL is up about 8x?
Will AVXL win? Yes. This is not beta v. vhs: the much better molecule does win in the end. AVXL has the better molecule.
A couple of points as I also own $ACAD and advocate for the rare disease communities. The approval of Trofinetide was a major event being first to market and exciting for the community to finally have a drug to try. I personally wish them all the best with the treatment and working through the adverse side effects. Sales will flatten out after the initial surge. IMO, the key market cap driver for $ACAD is the growing prescribing rate for Nuplazid, Trofinetide was a nice bonus.
My father technically had Lewy Body Dementia one of the diseases associated with Neurological Synuclein Disease (NSD). Expect to see this term NSD used more in the literature, probably starting next year, as the Michael J Fox Foundation and many other stakeholders are making attempts to better understand and diagnose the diseases caused by alpha-synuclein misfolding. This project will improve availability and further fuel Nuplazid sales growth.
Blarcamesine has a completely different mechanism of action and will be a complementary treatment used with both Nuplazid and Trofinetide and more than likely blarcamesine will become the first line treatment.
"Ah, the good old days" ... So much has changed from the retail perspective over my 30 years in the industry. Many of my old tasks are automated and free to the retail consumer.
But I digress, the original topic was accounting for the cost of capital and rising interest rates and it's true that from the retail perspective "shorting" can seem free for widely held securities, but we all know the industry gives NOTHING away for free. Understand that it is in the back end operations and accounting in aggregate is where the broker earns a return. ;)
BTW, I saw the whole electronic revolution over my career that started in 1994 when "telebroker" and $55 for 100 share trade was a huge discount.
Ah where's my blarcamesine is the question I ask now?
Quick comment on margin and shorting. You may not have been charged interest , but depending on your broker and position size, I guarantee the MVS (Market Value Short) was segregated out so that value would not be able to earn interest, and by doing such the broker net earned interest.
Shorts are loosing money on interest costs.
A sound plan based upon the technical analysis picture and a shorter term trader timeframe.
Did you reload?
I may reload at 7.80
Drugs categorized as biologics have always received special treatment in terms of rewards and as this article shows gaining the system for their benefit for maximum effect.
Indeed, Anavex has consulted with the FDA on trial designs and when they finally get around to turning in their assignment a NDA, the FDA will give it a fair review.
Regarding the current market cap, in my opinion its value has moved in tandem with the $XBI and sector in general, therefore it's a fair valuation in a fair market.
Indeed, this line has been on my profile since my account was created. I have learned a lot from a few select aliases.
Listen and learn from people from all walks of life and backgrounds.
Trading got weird as dark pools went from the exception to the norm, then add in the lack of controls in the stock loan and shorting system and here we are... embrace it and adapt, or quit is my opinion to most rookie single stock wanna be traders.
There have been several attempts at doing that. I remember Island exchange from many years ago.
It was a no MM exchange that the day traders used a lot. You could see what was offered and bid or offer your own stock at whatever price you wanted. When the two matched up a trade was executed.
It was eventually bought out by and became a dark pool IIRC.
Nobody exercises early, especially when cash is paying such historically high interest rates.
I am aware of the July 5th expiration....but since he is vested he can exercise before that date, he does NOT need to wait.....
Sure if you wanna miss out on a $$8.50 bounce, those are fine fib targets....
"Reload" so you are at a zero position?
I may reload at 7.80
I'm of the opinion the status quo of trading operations will remain the same and until the system has been legally reformed ,there is little desire to "rock the boat" from anyone.
It is an opportunity bound to be taken advantage of by someone entrepreneurial and prepared to rock the boat.
We debate many things here, so it's always nice to see agreement and consensus on a topic.
I sound like a cantankerous old man, but the back office plumbing of the equity markets needs reform particularly when there are only a few market centers that control the vast majority trade executions, and both them AND the DTCC both resist such reforms. There is legal crookery afoot.
I personally enforced the REGSHO report back in the olden days and it was adequate to solve retail level failures to deliver, but for the crooks of the industry to claim there are adequate controls that is complete BS and everyone knows it.
In the meantime, as I say often, embrace the volatility and trade like the crooks do.
I swear everything went wonky in equity markets as "payment for order flow" took over as the industry model. I'm so glad I retired early from that crap to become my dad's dementia caregiver.
In other words, today Anavex stated that,
some research has taken place as a positive activity to benefit future Rett trials.
Great, and I'm making the point Anavex will use the same measurements used in the trofinetide approval, in addition to the methodologies and methods described in the paper.
Hence, it may not be possible to rearrange them to the new sub-scales in any meaningful way